Wedbush Reiterates HTWR Rating as Outperform

Wedbush Securities has published a research report on HeartWare International HTWR and reiterates its rating on the company at Outperform. In the report, Wedbush writes, “Our fair value of $105 per share is calculated using a sum-of-parts analysis applying 1-5 multiple and a 20-25% annual discount to our HVAD sales in 2012 (EU) or two-years post approval (US). Given the groundbreaking nature of HeartWare's HVAD, the enthusiastic response from surgeons, and the lack of near-term financing risk, we reiterate our OUTPERFORM rating.” HTWR closed Friday at $64.41.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsWedbush Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!